News & Views

Telix today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer.

Telix today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.

Telix and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing integrated theranostics solutions.

Telix announces the oral presentation of Part 1 safety, dosimetry and pharmacokinetics data from the ProstACT Global Phase 3 Study of TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), in metastatic castration-resistant prostate cancer (mCRPC). The late-breaking data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois by study Principal Investigator Pedro C. Barata, MD, Medical Oncologist, University Hospitals Seidman Cancer Center and Associate Professor of Medicine, Case Western Reserve University of School of Medicine, Cleveland, Ohio. 

Craig Stankiewicz is a husband, father and business professional from Chicago, Illinois. In August 2021, Craig was diagnosed with glioblastoma (GBM) and almost five years on he continues to face the disease, using his experience to help others with the same diagnosis.

Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago. ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of ProstACT Global, Telix’s Phase 3 study of TLX591-Tx (177Lu-rosopatamab tetraxetan) in combination with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer.

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting. This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel imaging approaches in clear cell renal cell carcinoma, thyroid cancer and bone marrow dosimetry.

Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies Global Healthcare Conference in New York, NY.

Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother, Sandra was diagnosed with glioblastoma (GBM) in 2016 and passed away the same year — less than nine months after diagnosis. We spoke to Courtney about her family’s journey, the challenges of navigating a GBM diagnosis, and the work she does every day to make sure no one faces this disease alone.

Telix today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including with two doses of 5GBq (total administered activity of 10GBq), the maximum administered dose in the study.